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LETTER TO THE EDITOR
Good Outcome after Digoxin Toxicity Despite Very 
High Serum Potassium Level 
 
 
Dear Editor, 
Digoxin, as a cardiac glycoside extracted from the 
Digitalis lanata
1 is widely used in the treatment of 
different heart diseases, such as atrial fibrillation, 
atrial flutter and heart failure.
2 Its effect is to increase 
myocardial contractility while mildly prolonging the 
duration of contraction. The result is decreased heart 
rate, increased blood pressure and stroke volume, 
leading to increased tissue perfusion, improved myo-
cardial function and hemodynamics.
2 Digoxin inter-
acts with verapamil, amiodarone, and erythromycin, 
leading to increase in its plasma level.
3 Arrhythmo-
genesis and atrio-ventricular conduction arrhythmias 
such as paroxysmal atrial tachycardia with A-V block 
are diagnostic for digoxin toxicity.
4 Without the use 
of digoxin-specific Fab fragments, in a recent review, 
mortality after digoxin toxicity have been reported to 
be zero in patients with acute digoxin toxicity and po-
tassium levels less than 5.0 meq/dl, 50% in potassium 
levels between 5.0 and 5.5, and 100 percent in those 
with potassium levels above 5.5 meq/dl.
5 Serum potas-
sium levels above 5.0 meq/dl in patients with acute 
cardiac digoxin toxicity has been proposed as an abso-
lute indication for digoxin-specific Fab fragments.
5 We 
present a case of acute digoxin toxicity with high po-
tassium level and good outcome despite unavailability 
of digoxin-specific Fab fragments. 
The patient was a 75 year-old lady, who was ad-
mitted in intensive care unit (ICU) for management of 
respiratory failure after pulmonary emboli and pul-
monary arterial hypertension. She had tracheostomy 
tube due to prolonged mechanical ventilation and her 
Glascow Coma Score was 11. The patient was receiv-
ing digoxin 0.25 mg daily via nasogastric tube for 
treatment of right sided heart failure. In ICU course 
due to feeding intolerance and decreased gastric mo-
tility, intravenous erythromycin (500 mg every 6 
hours) was started as a prokinetic agent. Two days 
later, probably as a complication of drug interaction 
(digoxin and erythromycin), she developed vomiting, 
diarrhea, bradycardia, atrial fibrillation in favor of 
digoxin toxicity (Figure 1).  
In her concomitant lab-data, serum potassium was 
reported 6.6 meq/l and repeated sample confirmed 
hyperkalemia (6.5 meq/lit); no hemolysis was report-
ed and samples were taken from central venous line. 
So digoxin was hold and its serum level was checked 
with HPLC (High Performance Liquid Chromatog-
raphy) method which was 3.2 ng/ml, in favor of di-
goxin toxicity (serum more than 2 ng/ml is consid-
ered as toxic range).  
After holding digoxin and supportive management 
(close EKG monitoring, holding maintenance intra-
venous KCl, and administration of 50% dextrose-
regular insulin intravenously to control hyperkalemia) 
but without the use of 'digoxin-specific Fab frag-
ments' (unfortunately digifab was unavailable at that 
time), signs and symptoms of digoxin toxicity was 
relieved and the patient survived despite concomitant 
high serum potassium 6.6 meq/l.  
Digoxin effect is to increase intracellular amounts 
of Ca
2+ ions and K
+ conductance.  Other effects of 
this drug are increase in the refractory period of sino-
atrial and AV nodes, decreasing it in the atria and ven-
 
 
Fig. 1: Atrial fibrillation. EKG of the Patient concomitant to “digoxin toxicity”. Digoxin toxicity 
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tricles, and so increase in excitability. It also decreases 
the conduction of electrical impulses through the AV 
node by vagal stimulation leading to negative chrono-
tropic effect.
6 
Digoxin decreases the function of α-subunit of the 
Na
+/K
+ ATPase pump in the membranes of heart my-
ocytes by binding to it. So the level of the sodium 
ions in the myocytes increases, and as a consequence 
of sodium/calcium exchanger function intracellular 
calcium ions rise. Increased amount of Ca
2+ storing in 
the sarcoplasmic reticulum  leads to increased con-
tractility of the heart.
7 Digoxin is used in congestive 
heart failure, especially in patients with refractory 
symptoms along with diuretic and ACE inhibitor 
treatment, but it is ineffective at decreasing morbidity 
and mortality while  improving the quality of life.
2 
Safe therapeutic plasma level is 1-2.6 nmol/l. Di-
goxin plasma level should be checked in the setting of 
questioned toxicity or ineffectiveness. Plasma potas-
sium levels should be monitored frequently.
2  Due to 
narrow therapeutic index, the dose-dependent adverse 
effects (rare if plasma digoxin concentration is <0.8 
μg/l) are common.
8 Hypokalemia increases the risk 
because digoxin competes with K
+ for binding to the 
Na
+/K
+ ATPase pump.
9 In overdose, supportive care 
should be undertaken. Digoxin antidote is digibind 
and digifab which is given in life threatening ar-
rhythmias or malignant hyperkalemia which defines 
as unavoidably increasing potassium level owing to 
paralysis of the cell membrane bound ATPase-
dependent Na/K pumps.
10 EKG findings are increased 
PR interval, decreased QT interval, inverted T wave 
and ST depression. Other changes are AV junctional 
rhythm and ectopic beats (bigemminy) leading to 
ventricular tachycardia and fibrillation.
2 
Digoxin toxicity should be considered when de-
ciding to start any new medication in a patient on di-
goxin therapy especially in ICU settings where poly 
pharmacy is not uncommon. Patients with acute car-
diac glycoside toxicity and hyperkalemia especially 
those with serum potassium level above 5.5 meq/lit 
have a grave prognosis, but early and aggressive sup-
portive therapy my significantly improve the outcome 
despite unavailability of digifab. 
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